Nebenwirkungen · Caelyx pegylated liposomal
Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-085583 · Präparat HOS-083155
In patients with solid tumours, including a subset of patients with breast and ovarian cancers, treated at a dose of 50 mg/m2/cycle with lifetime cumulative anthracycline doses up to 1,532 mg/m2, the incidence of clinically significant cardiac dysfunction was low. Of the 418 patients treated with Caelyx pegylated liposomal 50 mg/m2/cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of > 400 mg/m2, an exposure level associated with an
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-24T17:56:00Z · SHA-256 c7886f3f50305fcb29bfb2c8de51dd65f782908ce31d2fdd422d43a9ccecfc7e · Passage 5e70e072a3a810be74ff4a64bdae6da6831d408e14cebcaaf1be1f535056d24e · Zeichen 16602–17184 im Abschnitt